Boston Cambridge Biotech Networks

Just two more days to buy tickets to BioversityMA fundraising event this Wednesday, July 31st. Join us from 5-8pm at Southline Boston in Dorchester to celebrate the first six months of Bioversity's operations, the graduating of 43 students, and the growing placements of our graduates into early career life sciences jobs and the launch of their new careers. At the Celebrate Bioversity! event, you'll hear from three of our graduates about their experience at Bioversity and now in their new careers. And special guest MassBio Board Chair Tamar Thompson from Alexion Pharmaceuticals, Inc. will give remarks as well. Thank you to our sponsors for making this event possible and to the 180+ people who have RSVP'd already. Your support helps secure the future impact of Bioversity as we look to grow and become more sustainable. Blueprint Medicines Foundation Medicine Johnson & Johnson MassBio Boston Lab Services Entrada Therapeutics LabOps Unite Community Organogenesis Thermo Fisher Scientific Buy your tickets here: https://lnkd.in/eUJhtjY5 (Bioversity is a 501c3 public charity) Ross Marshall

BCBN Feed: Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024 https://lnkd.in/gAHrWcrc ADELAIDE, Australia and CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it... ... [...]

BCBN Feed: T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor https://lnkd.in/g_AQB5iC LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in Malaysia and Indonesia. Under the terms of the agreement, T2 Biosystems will sell... ... [...]

BCBN Feed: MIT spinout Arnasi begins applying LiquiGlide no-stick technology to help patients https://lnkd.in/gG9U5tEZ The company that brought you no-stick toothpaste is moving into the medical space, with a lubricant for ostomy pouches and other products that could improve millions of lives. ... [...]

BCBN Feed: Versatope Receives Grants to Support Malaria Vaccine Development https://lnkd.in/gnCqe32m LOWELL, Mass., July 29, 2024 /PRNewswire/ -- Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today it has received a Phase 2 Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and... ... [...]

BCBN Feed: Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition https://lnkd.in/gEGpmcm3 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #alzheimers--Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition ... [...]

BCBN Feed: Quanterix Presents Data Demonstrating Successful Multi-Marker Approach for Alzheimer’s Disease Detection that is More Effective than Standalone Plasma p-Tau 217 https://lnkd.in/guT-qmmg BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today presented new data at the Alzheimer’s Association International Conference (AAIC), supporting a novel multi-marker approach to test for Alzheimer’s disease (AD). For the first time, new data show that applying a combination of AD-relevant... ... [...]

BCBN Feed: Cognition’s phase 2 SHINE data tarnish Alzheimer’s prospect with mere ‘signals’ of improvement https://lnkd.in/gv9aUqcr Cognition Therapeutics’ phase 2 SHINE trial has taken some of the luster off the Alzheimer’s disease drug candidate CT1812. The oral sigma-2 antagonist failed to statistically beat placebo—or clear Cognition’s own bar for success—on the main efficacy endpoint that focused on symptom severity, but the biotech wants to forge... ... [...]

BCBN Feed: VC dollars pour into biopharma, with Q2 haul signaling sunshine ahead https://lnkd.in/gKnJX2eq With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally. Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank. Biopharmas raised... ... [...]

BCBN Feed: AeroShield Materials Announces Opening of New Manufacturing Facility, $5M Additional Funding to Produce Cutting-Edge, Energy Efficient Technology for Built Environment https://lnkd.in/gC_-f8_e WALTHAM, Mass,--(BUSINESS WIRE)--AeroShield Materials, an MIT spin out developing cutting-edge technology for energy efficiency applications in the built environment, announced today the opening of their new manufacturing facility in Waltham, Massachusetts and the close of $5M in additional funding with participation from existing investors Massachusetts Clean Energy Center and MassVentures... ... [...]